Publications by authors named "Xavier Gitton"

Claim this Profile
T
Two prospective, multicenter studies for the identification of biomarker signatures for early detection of pulmonary hypertension (PH): The CIPHER and CIPHER-MRI studies.
Allan Lawrie, Kelly Chin, Yiu-Lian Fong, Cynthia Gargano, Xavier Gitton

Pulm Circ· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electrocardiogram Detection of Pulmonary Hypertension Using Deep Learning.
Mandar A Aras, Sean Abreau, Hunter Mills, Lakshmi Radhakrishnan, Liviu Klein, Xavier Gitton

J Card Fail· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study.
Rieke Alten, Juan Gomez-Reino, Patrick Durez, Andre Beaulieu, Anthony Sebba, Xavier Gitton

BMC Musculoskelet Disord· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of canakinumab in the cryopyrin-associated periodic syndrome.
Helen J Lachmann, Isabelle Kone-Paut, Jasmin B Kuemmerle-Deschner, Kieron S Leslie, Eric Hachulla, Xavier Gitton

N Engl J Med· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen.
Michael E Farkouh, Freek W A Verheugt, Sean Ruland, Howard Kirshner, Raban Jeger, Xavier Gitton

J Clin Hypertens (Greenwich)· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials.
Stephen Daniels, Xavier Gitton, Wenchun Zhou, Kirstin Stricker, Scott Barton

J Womens Health (Larchmt)· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
Christopher J Hawkey, Wilfred M Weinstein, Walter Smalley, Xavier Gitton, Peter Sallstig

Gastroenterology· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
Maxime Dougados, Alan Moore, Shaohua Yu, Xavier Gitton

Arthritis Res Ther· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
Christopher J Hawkey, Xavier Gitton, Godehard Hoexter, Dominik Richard, Wilfred M Weinstein

Clin Gastroenterol Hepatol· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
Patrice Matchaba, Xavier Gitton, Gerhard Krammer, Elena Ehrsam, Victor Schorr Sloan

Clin Ther· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies.
Thomas J Schnitzer, Xavier Gitton, Sumedha Jayawardene, Victor S Sloan

Curr Med Res Opin· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
Thomas J Schnitzer, Gerd R Burmester, Eduardo Mysler, Marc C Hochberg, Michael Doherty, Xavier Gitton

Lancet· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
Michael E Farkouh, Howard Kirshner, Robert A Harrington, Sean Ruland, Freek W A Verheugt, Xavier Gitton

Lancet· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
Christopher C Hawkey, Petr Svoboda, Irena F Fiedorowicz-Fabrycy, Evgeny L Nasonov, Eduard G Pikhlak, Xavier Gitton

J Rheumatol· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Thomas J Schnitzer, Jannie Beier, Piet Geusens, Paul Hasler, Sanjay K Patel, Xavier Gitton

Arthritis Rheum· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis